4//SEC Filing
Landau Jeffrey B 4
Accession 0001610717-23-000410
CIK 0001501989other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 7:56 PM ET
Size
8.8 KB
Accession
0001610717-23-000410
Insider Transaction Report
Form 4
Landau Jeffrey B
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2023-12-17+11,250→ 90,699 total - Exercise/Conversion
Performance Stock Units (PSUs)
2023-12-17−11,250→ 11,250 total→ Common Stock (11,250 underlying)
Holdings
- 4,500(indirect: By IRA)
Common Stock
- 3,180(indirect: By IRA)
Common Stock
Footnotes (4)
- [F1]Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
- [F2]Includes 52,205 restricted stock units.
- [F3]Includes 1,310 shares and 1,760 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively.
- [F4]Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.
Documents
Issuer
CytomX Therapeutics, Inc.
CIK 0001501989
Entity typeother
Related Parties
1- filerCIK 0001918615
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 7:56 PM ET
- Size
- 8.8 KB